Biotech Bulls & Breakthroughs
Biotech Bulls & Breakthroughs
Podcast Description
Welcome to Biotech Bulls & Breakthroughs! This brand new podcast from BioPharmCatalyst explores the dynamic world of biotech investing alongside long-time biotech trader Sheff from Sheff Station. Each month, we will be discussing current events in the biotech industry and how these events impact investors, as well as a discussion of upcoming catalysts in the biotech space.
Podcast Insights
Content Themes
The podcast focuses on current events and trends within the biotech industry, emphasizing topics such as market volatility, FDA regulations, and emerging therapies. Specific episodes tackle issues like the impact of tariffs on drug manufacturing, the dynamics of GLP-1 medications, and upcoming catalysts that may affect biotech stocks, providing valuable insights for investors.
Welcome to Biotech Bulls & Breakthroughs! This brand new podcast from BioPharmCatalyst explores the dynamic world of biotech investing alongside long-time biotech trader Sheff from Sheff Station. Each month, we will be discussing current events in the biotech industry and how these events impact investors, as well as a discussion of upcoming catalysts in the biotech space.
In this episode of Biotech Bulls and Breakthroughs, host John Gagliano speaks with Annalee Armstrong, Senior Editor at BioSpace, about the current state of the biopharma industry. They discuss exciting developments in neurodegenerative diseases, the hype surrounding GLP-1 drugs, the future of oncology, the psychedelic drug market, the role of the FDA, and the impact of AI on drug discovery. Annalee emphasizes the need for certainty in the biotech industry and the importance of focusing on good science amidst the current uncertainties.
Follow BioSpace's Senior Editor Annalee Armstrong:
https://www.linkedin.com/in/annalee-armstrong
https://www.biospace.com/annalee-armstrong
In this episode:
Alzheimer's is seeing exciting developments. GLP-1 drugs currently overshadow other critical therapeutic areas. The psychedelic drug market has potential but faces monetization challenges.
Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar
Listen to more episodes: https://www.biopharmcatalyst.com/podcast
See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades
Follow BioPharmCatalyst: https://x.com/BPharmCatalyst Follow Sheff: https://x.com/SheffStation
Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.